Velaxin (venlafaxine) in the treatment of anxious depression
Il'ina, N.A.
Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova 108(3): 24-28
2008
ISSN/ISBN: 1997-7298 PMID: 18427537 Document Number: 615126
Thirty patients (7 mate, 23 female) mean age 35,3 +/- 7,8 years with anxious or anxious-apathic depression, including 24 in-patients and 6 out-patients. They were treated during 8 weeks with velaxin in dosage 225-375 mg per day. The changes of patient state evaluated with rating scales (CGI, HDRS, BDI, HADS-21). Twenty-seven patients (90%) completely underwent the course of treatment. Responders according to CGI were 25 (83,3%) cases: "improvement" - 16 (59,3%), "apparent improvement" - 9 (33,3%); "minor improvement" - 2 (7,4%) patients. The complete reduction of depressive symptoms was recorded in 33,3% of cases. The safety of velaxin in moderate therapeutic doses as well as improvement of laboratory and instrumental characteristics of somatic state was confirmed.